Industries > Pharma > Gene Therapy R&D and Revenue Forecasts 2020-2030

Back to Pharma Reports

Gene Therapy R&D and Revenue Forecasts 2020-2030

Retroviruses, Lentiviruses, Adenoviruses, Adeno Associated Virus, Herpes Simplex Virus, Poxvirus, Vaccinia Virus, Naked/Plasmid Vectors, Gene Gun, Electroporation, Lipofection, Cancer, Rare Diseases, Cardiovascular Disorders, Ophthalmologic Conditions, Infectious Disease, Neurological Disorders, Diabetes Mellitus

PUBLISHED: 06 March 2020

PAGES: 215

PRODUCT CODE: PHA0717

SUBMARKET: Biotechnology Next Generation Technologies Therapeutic Drugs

SKU: PHA0717 Categories: Biotechnology, Next Generation Technologies, Pharma, Therapeutic Drugs Tags: PHA0717, PHA1071, PHA1078, PHA1123, PHA1134

The gene therapy market is projected to grow at a CAGR of 32% in the first half of the forecast period. In 2019, the cancer treatment submarket accounted for 55.8% of the gene therapy drug market. Visiongain estimated that gene therapy for rare diseases will be the driver for market growth in the first half of the forecast period.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand-new 215-page report you will receive 157 charts– all unavailable elsewhere.

The 215-page report provides clear detailed insight into the gene therapy market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Gene Therapy market forecasts from 2020-2030

• This report assesses the approved gene therapy products in the market and gives revenue to 2030

• Provides qualitative analysis and forecast of the submarket by indication for the period 2020-2030:
• Cancer
• Cardiovascular disorders
• Rare diseases
• Ophthalmological diseases
• Infectious Diseases
• Neurological Disorders
• Diabetes Mellitus
• Other therapeutic uses

• Profiles leading companies that will be important in the development of the gene therapy market. For each company, developments and outlooks are discussed and companies covered in this chapter include:
• UniQure
• Biogen
• Bluebird Bio
• Spark Therapeutics
• Applied Genetics Technologies Corporation
• Oxford Biomedica
• GenSight Biologics
• & Other Companies

• Assesses the outlook for the leading gene treatment R&D pipeline for 2019 and discusses technological progress and potential. Profiles appear for gene therapy drug candidates, with revenue forecasts for four leading agents:
• Collategene (AMG0001, AnGes MG/Vical)
• BC-819 (BioCancell)
• BC-821 – BioCancell
• SPK-CHM – Spark Therapeutics
• SPK-FIX – Spark Therapeutics/Pfizer
• SPK-TPP1- Spark Therapeutics
• Lenti-D (Bluebird Bio)
• LentiGlobin (Bluebird Bio)
• VM202-DPN – ViroMed

• Provides qualitative analysis of trends that will affect the gene therapies market, from the perspective of pharmaceutical companies, during the period 2020 to 2030. SWOT analysis is provided and an overview of regulation of the gene therapy market by leading region given.

• Our study discusses factors that influence the market including these:
• Translation of research into marketable products modifying human DNA – gene transfer for therapeutic use, altering the nuclear genome
• Genomic editing technology and other supporting components
• Collaborations to develop and launch gene-based products – acquisitions and licensing deals
• Supporting technologies for human genetic modification, gene replacement and targeted drug delivery
• Gene therapies for ophthalmologic diseases – next-generation medicines
• Regulations in the United States, the European Union and Japan – overcoming technological and medical challenges to pass clinical trials.

Visiongain’s study is intended for anyone requiring commercial analyses for the gene therapy market. You find data, trends and predictions.

Buy our report today Gene Therapy R&D and Revenue Forecasts: Retroviruses, Lentiviruses, Adenoviruses, Adeno Associated Virus, Herpes Simplex Virus, Poxvirus, Vaccinia Virus, Naked/Plasmid Vectors, Gene Gun, Electroporation, Lipofection, Cancer, Rare Diseases, Cardiovascular Disorders, Ophthalmologic Conditions, Infectious Disease, Neurological Disorders, Diabetes Mellitus.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

1. Report Overview

1.1 Global Gene Therapy Market Overview

1.2 Benefits of This Report

1.3 How This Report Delivers

1.4 Key Questions Answered by This Analytical Report

1.5 Who is This Report For?

1.6 Methods of the Study

1.7 Frequently Asked Questions (FAQ)

1.8 Associated Visiongain Reports

1.9 About Visiongain

2. Introduction to Gene Therapy

2.1 What is Gene Therapy?

2.2 Types of Gene Therapy

2.3 Products Excluded from the Report

2.4 Gene Therapy Vectors

3. Gene Therapy World Market: Leading Treatments and Forecasts, 2017-2028

3.1 The World Market for Gene Therapy: Overview of Products

3.2 Luxturna

3.3 Kymriah

3.4 Yescarta

3.5 Zolgensma

3.6 Gendicine (rAd-p53) – The First Gene Therapy to Market

3.7 Oncorine: Growth is Hindered by Certain Factors

3.8 Neovasculgen: Russia’s First Gene Therapy

3.8.1 Neovasculgen: Historical Performance and Revenue Forecast, 2019-2030

3.9 Strimvelis: Second Gene Therapy for an Inherited Disease Ever to be approved for Sale and the First Corrective Gene Therapy for Children to be Approved Anywhere in the World

3.10 Glybera

4. Gene Therapy World Market: By Vector and Forecasts, 2020-2030

4.1 Viral Vectors

4.1.1 Retroviruses

4.1.2 Lentiviruses

4.1.3 Adenoviruses

4.1.4 Adeno Associated Virus

4.1.5 Herpes Simplex Virus

4.1.6 Poxvirus

4.1.7 Vaccinia Virus

4.2 Non-Viral Vector

4.2.1 Naked/Plasmid Vectors

4.2.2 Gene Gun

4.2.3 Electroporation

4.2.4 Lipofection

5. Gene Therapy World Market and Disease Submarkets, 2019-2030

5.1 The Global Market for Gene Therapy Drug Treatments in 2019

5.2 Gene Therapy Market Forecast, 2019-2030

5.3 Gene Therapy for Cancer

5.3.1 Clinical Trials for Cancer

5.3.2 The Cancer Gene Therapy Treatment Submarket Forecast 2019-2030

5.4 Gene Therapy for Rare Diseases

5.4.1 The Rare Disease Treatment Submarket Forecast 2019-2030

5.5 Gene Therapy for Cardiovascular Diseases

5.5.1 The Cardiovascular Disease Treatment Submarket Forecast 2019-2030

5.6 Gene Therapy for Ophthalmologic Diseases

5.6.1 Advanced Stage Gene Therapies for Ophthalmologic Diseases

5.6.2 The Ophthalmologic Disease Treatment Submarket Forecast 2019-2030

5.7 Gene Therapy for Infectious Diseases

5.7.1 Infectious Diseases Submarket Forecast 2019-2030

5.8 Gene Therapy for Neurological Disorders

5.8.1 Neurological Disorders Submarket Forecast 2019-2030

5.9 Gene Therapy for Diabetes Mellitus

5.9.1 Diabetes Mellitus Submarket Forecast 2019-2030

5.10 Gene Therapy for Other Diseases

5.10.1 The Other Disease Treatment Submarket Forecast 2019-2030

5.10.2 Changing Market Shares: Cancer Disease Gene Therapies Will Dominate and Become Market Leader

6. Gene Therapy World Market: by Region Forecasts, 2020-2030

6.1 Leading Regional Markets of Gene Therapy 2019-2030

6.2 North America

6.3 Europe

6.4 Asia Pacific

6.5 Latin America

6.6 MEA

7. R&D Pipeline Analysis and Forecasts, 2019-2030

7.1 Pipeline

7.2 Pipeline Analysis

7.3 Collategene (AMG0001) - AnGes MG/Vical

7.4 BC-819 - BioCancell

7.5 BC-821 - BioCancell

7.6 Lenti-D - Bluebird Bio

7.7 LentiGlobin (LentiGlobin BB305) - Bluebird Bio

7.8 SPK-CHM - Spark Therapeutics

7.9 SPK-FIX - Spark Therapeutics/Pfizer

7.10 SPK-TPP1- Spark Therapeutics

7.11 VM202-DPN - ViroMed

7.12 Important Pipeline Technology Developments

7.13 Clustered regularly interspaced short palindromic repeats (CRISPR)

7.14 The Future of the Gene Therapy Pipeline

8. Companies of Interest in the Gene Therapy Market: Robust Pipelines Will Yield Revenue in the Future

8.1 UniQure B. V. - the First Commercial Stage Gene Therapy Company in the West

8.2 Biogen - Focusing on Ophthalmologic and Rare Disease Gene Therapies

8.2.1 Biogen: Financial Performance 2015-2018

8.2.2 Biogen: Key News

8.3 Bluebird Bio: Gene Editing Technology

8.4 Spark Therapeutics- Strong Change to Become the First Company with Marketed Gene Therapy in the US

8.5 Applied Genetic Technologies Corporation: Specialisation in Ophthalmologic Diseases

8.6 Oxford Biomedica: Collaboration as a Strategy

8.7 GenSight Biologics - Novel Mitochondrial Technology Platform

8.8 Celgene Corporation

8.8.1 Celgene Corporation: Financial Overview

8.9 GlaxoSmithKline plc.

8.9.1 GlaxoSmithKline plc: Financial Overview

8.9.2 GlaxoSmithKline plc: Recent Transactions Summary

8.10 Takeda Pharmaceuticals

8.10.1 Takeda Pharmaceuticals: Financial Overview

8.10.2 Takeda Pharmaceuticals: Key News

8.11 Cellectis

8.11.1 Cellectis: Key News

8.12 Sangamo Therapeutics, Inc.

8.12.1 Sangamo Therapeutics, Inc: Key News

8.13 REGENXBIO Inc.

8.13.1 REGENXBIO Inc.: Key News

8.14 Voyager Therapeutics

8.14.1 Voyager Therapeutics: Key News

8.15 Bristol Myers Squibb

8.15.1 Bristol-Myers Squibb Company: Financial Overview

8.15.2 Bristol-Myers Squibb Company: Recent Transactions Summary

8.16 Genzyme Corporation

8.16.1 Genzyme Corporation: Key News

8.17 Chiesi Farmaceutici S.p.A

8.17.1 Chiesi Farmaceutici S.p.A: Key News

8.18 Benitec BioPharma

8.18.1 Benitec BioPharma: Key News

8.19 Gene Therapy and Big Pharma: Collaborations

9. Research Interviews

9.1 Kyriacos Mitrophanous, Chief Scientific Officer at Oxford Biomedica

9.1.1 Oxford Biomedica

9.1.2 Gene therapy landscape

9.1.3 Oxford Biomedica LentiVector ®

9.1.4 Pricing and Next Steps in Gene Therapy

9.2 Professor Dusko Ilic, Professor of Stem Cell Science, King's College London

9.2.1 Gene therapy landscape

9.2.2 Ethical Considerations with Gene Therapy

9.2.3 Regulation & Pricing of Gene Therapy Products

10. Qualitative Analysis of the Gene Therapy Market, 2020-2030

10.1 SWOT Analysis of the Gene Therapy Treatment Market, 2020

10.2 Strengths: A Vast Pipeline for a Wide Range of Indications

10.3 Weaknesses: Low Patient Populations Cannot Sustain Long-Term Growth

10.4 Opportunities and Threats for the Gene Therapy Drug Market, 2020-2030

10.5 Opportunities: Collaborations and Novel Technologies Will Pave the Way

10.6 Threats: Expensive Drugs with Strict Regulations

10.7 Regional markets: Regulation of the Gene Therapy Market

10.7.1 Gene Therapy Regulations: Evolving with the Market

10.7.2 US Regulations: Strict Regulation of a Cautious Market

10.7.3 EU Regulations: One Approval So Far

10.7.4 Japanese Regulations: A Rigorous Process

10.7.5 China Has Highest Gene Sequencing Capacity

11. Conclusions

11.1 The World Gene Therapy Treatment Market: Current World Outlook

11.1.1 Driver for Growth to 2030: A Vast Pipeline of Gene Therapy Products

11.1.2 Leading Gene Therapy Treatment Submarkets and Products, 2019-2030

11.1.3 Leading Regional Markets and Companies: Partnerships Will Achieve Success

11.2 The Future of the Gene Therapy Treatment Market

Associated Visiongain Reports

Visiongain Report Sales Order Form

About Visiongain

Visiongain report evaluation form

List of Tables

Table 3.1 Approved Gene Therapies, 2019

Table 3.2 Luxturna Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030

Table 3.3 Kymriah Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030

Table 3.4 Yescarta Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030

Table 3.5 Zolgensma Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030

Table 3.6 Gendicine Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030

Table 3.7 Gene Therapies in Pipeline, 2019

Table 3.8 Oncorine Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030

Table 3.9 Neovasculgen Historical Revenue Comparisons, Revenue ($m), AGR (%), 2014-2018

Table 3.10 Neovasculgen Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030

Table 3.11 Strimvelis Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030

Table 4.1 Viral Vector Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030

Table 4.2 Retroviruses Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030

Table 4.3 Lentiviruses Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030

Table 4.4 Adenoviruses Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030

Table 4.5 Adeno Associated Virus Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030

Table 4.6 Herpes Simplex Virus Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030

Table 4.7 Poxvirus Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030

Table 4.8 Vaccinia Virus Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030

Table 4.9 Non-Viral Vector Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030

Table 4.10 Naked/Plasmid Vectors Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030

Table 4.11 Gene Gun Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030

Table 4.12 Electroporation Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030

Table 4.13 Lipofection Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030

Table 5.1 Leading Gene Therapy Drugs by Revenue ($bn), 2019

Table 5.2 World Market Forecasts for Gene Therapy Drugs by Indication, Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2019-2030

Table 5.3 Selected Anti-Angiogenic Gene Therapy Using a Non-Viral Vector, 2019

Table 5.4 Selected Anti-Angiogenic Gene Therapy Using a Retroviral Vector, 2019

Table 5.5 Selected Anti-Angiogenic Gene Therapy Using an Adenoviral Vector, 2019

Table 5.6 Selected Anti-Angiogenic Gene Therapy Using an Adeno-Associated Virus Vector, 2019

Table 5.7 Selected Anti-Angiogenic Gene Therapy Using Lentiviral Vector, 2019

Table 5.8 Global Gene Therapy Clinical Trials by Indication, 2019

Table 5.9 Selected Cancer Gene Therapies in Phase 2 and Phase 3 Clinical Trial Development, 2019

Table 5.10 Selected Cancer Gene Therapies in Phase 1 and Phase 1/2 Clinical Trial Development, 2019

Table 5.11 Global Gene Therapy Market: Revenue ($bn) and Market Shares (%) by Indication, 2019

Table 5.12 Global Market Forecast for Cancer Gene Therapies: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2019-2030

Table 5.13 Rare Diseases Gene Therapy Pipeline, 2019

Table 5.14 Global Market Forecast for Rare Disease Gene Therapies: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2019-2030

Table 5.15 Cardiovascular Gene Therapy Pipeline, 2019

Table 5.16 Global Market Forecast for Cardiovascular Disease Gene Therapies: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2019-2030

Table 5.17 Preclinical Ophthalmologic Pipeline, 2019

Table 5.18 Clinical Ophthalmologic Pipeline, 2019

Table 5.19 Additional Products in the Clinical Ophthalmologic Pipeline, 2019

Table 5.20 Global Market Forecast for Ophthalmologic Disease Gene Therapies: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2019-2030

Table 5.21 Preclinical Infectious Diseases Pipeline, 2019

Table 5.22 Global Infectious Diseases Market Forecast: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2019-2030

Table 5.23 Preclinical Neurological Disorders Pipeline, 2019

Table 5.24 Global Neurological Disorders Market Forecast: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2019-2030

Table 5.25 Preclinical Diabetes Mellitus Pipeline, 2019

Table 5.26 Global Diabetes Mellitus Market Forecast: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2019-2030

Table 5.27 Global Market Forecast for Other Disease Gene Therapies: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2019-2030

Table 5.28 Global Market Forecast for Gene Therapies by Indication: Market Shares (%), 2020-2025

Table 5.29 Global Market Forecast for Gene Therapies by Indication: Market Shares (%), 2025-20230

Table 6.1 World Gene Therapy Market, by Region: Revenue ($Bn) and Market Share (%) 2019 and 2030

Table 6.2 Global Gene Therapy Market Forecast, by Region: Revenue ($bn), AGR (%), CAGR (%), 2019-2030

Table 6.3 North America Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030

Table 6.4 Europe Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030

Table 6.5 Asia Pacific Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030

Table 6.6 Latin America Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030

Table 6.7 MEA Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030

Table 7.1 Promising Gene Therapies in Development, 2019

Table 7.2 Gene Therapies in Phase 3, 2019

Table 7.3 Collatagene Forecast, Revenue ($mn), AGR (%), CAGR (%), 2019-2030

Table 7.4 BC-819 Forecast, Revenue ($m), AGR (%), CAGR (%), 2019-2030

Table 7.5 Lenti-D Forecast, Revenue ($m), AGR (%), CAGR (%), 2019-2030

Table 8.1 UniQure B. V.: Overview, 2020

Table 8.2 uniQure Pipeline, 2020

Table 8.3 Biogen: Overview, 2020

Table 8.4 Bluebird Bio: Overview, 2020

Table 8.5 Spark Therapeutics: Overview, 2020

Table 8.6 Spark Therapeutics Collaborations, 2020

Table 8.7 Applied Genetic Technologies Corporation: Overview, 2020

Table 8.8 Oxford Biomedica: Overview, 2020

Table 8.9 Gensight Biologics: Overview, 2020

Table 8.10 Celgene Corporation: Overview, 2020

Table 8.11 GlaxoSmithKline plc: Overview, 2020

Table 8.12 Takeda Pharmaceuticals: Overview, 2019

Table 8.13 Cellectis: Overview, 2020

Table 8.14 Sangamo Therapeutics, Inc.: Overview, 2020

Table 8.15 REGENXBIO Inc.: Overview, 2020

Table 8.16 Voyager Therapeutics: Overview, 2020

Table 8.17 Bristol-Myers Squibb Company: Overview, 2020

Table 8.18 Genzyme Corporation: Overview, 2020

Table 8.19 Chiesi Farmaceutici S.p.A: Overview, 2020

Table 8.20 Benitec BioPharma: Overview, 2020

Table 8.21 Selected Big Pharma Collaborations in Gene Therapy, 2019

Table 9.1 Strengths and Weaknesses of the Gene Therapy Drug Treatment Market, 2020

Table 9.2 Gene Therapy Pipeline for Neurodegenerative Diseases, 2020

Table 9.3 Gene Therapy Pipeline for Metabolic Diseases, 2020

Table 9.4 Gene Therapy Pipeline for Musculoskeletal Diseases, 2020

Table 9.5 Gene Therapy Pipeline for Viral Diseases, 2020

Table 9.6 Opportunities and Threats of the Gene Therapy Drug Market, 2020

Table 9.7 Clinical Trials for Standard Drug Development Versus Orphan Drug Development, 2020

Table 10.1 World Gene Therapy Market, by Region: Revenue ($Bn) and Market Share (%) 2019 and 2030

List of Figures

Figure 1.1 Global Gene Therapy Market Segmentation Overview, 2020

Figure 2.1 Vectors Used in Gene Therapy Clinical Trials, 2019

Figure 3.1 Luxturna Market Forecast, Revenue ($bn), AGR (%), 2019-2030

Figure 3.2 Kymriah Market Forecast, Revenue ($bn), AGR (%), 2019-2030

Figure 3.3 Yescarta Market Forecast, Revenue ($bn), AGR (%), 2019-2030

Figure 3.4 Zolgensma Market Forecast, Revenue ($bn), AGR (%), 2019-2030

Figure 3.5 Gendicine Market Forecast, Revenue ($bn), AGR (%), 2019-2030

Figure 3.6 Oncorine Market Forecast, Revenue ($bn), AGR (%), 2019-2030

Figure 3.7 Neovasculgen Market Forecast, Revenue ($bn), AGR (%), 2019-2030

Figure 3.8 Strimvelis Market Forecast, Revenue ($bn), AGR (%), 2019-2030

Figure 4.1 Viral Vector Market Forecast, Revenue ($bn), AGR (%), 2019-2030

Figure 4.2 Retroviruses Market Forecast, Revenue ($bn), AGR (%), 2019-2030

Figure 4.3 Lentiviruses Market Forecast, Revenue ($bn), AGR (%), 2019-2030

Figure 4.4 Adenoviruses Market Forecast, Revenue ($bn), AGR (%), 2019-2030

Figure 4.5 Adeno Associated Virus Market Forecast, Revenue ($bn), AGR (%), 2019-2030

Figure 4.6 Herpes Simplex Virus Market Forecast, Revenue ($bn), AGR (%), 2019-2030

Figure 4.7 Poxvirus Market Forecast, Revenue ($bn), AGR (%), 2019-2030

Figure 4.8 Vaccinia Virus Market Forecast, Revenue ($bn), AGR (%), 2019-2030

Figure 4.9 Non-Viral Vector Market Forecast, Revenue ($bn), AGR (%), 2019-2030

Figure 4.10 Naked/Plasmid Vectors Market Forecast, Revenue ($bn), AGR (%), 2019-2030

Figure 4.11 Gene Gun Market Forecast, Revenue ($bn), AGR (%), 2019-2030

Figure 4.12 Electroporation Market Forecast, Revenue ($bn), AGR (%), 2019-2030

Figure 4.13 Lipofection Market Forecast, Revenue ($bn), AGR (%), 2019-2030

Figure 5.1 Gene Therapy World Market Forecast, Market Size ($bn), AGR (%), 2019-2030

Figure 5.2 Global Gene Therapy Clinical Trials by Indication, 2019

Figure 5.3 Cancer Gene Therapy Pipeline by Phase of Development, 2019

Figure 5.4 Global Gene Therapy Market: Market Shares (%) by Indication, 2019

Figure 5.5 Global Market Forecast for Cancer Gene Therapies: Revenue ($bn), 2019-2030

Figure 5.6 Rare Diseases Gene Therapy Pipeline by Phase of Development, 2020

Figure 5.7 Global Market Forecast for Rare Disease Gene Therapies: Revenue ($bn), 2019-2030

Figure 5.8 Cardiovascular Gene Therapy Pipeline by Phase of Development, 2019

Figure 5.9 Global Market Forecast for Cardiovascular Disease Gene Therapies: Revenue ($bn), 2019-2030

Figure 5.10 Global Market Forecast for Ophthalmologic Disease Gene Therapies: Revenue ($bn), 2019-2030

Figure 5.11 Global Infectious Diseases Market Forecast: Revenue ($bn), AGR (%), 2019-2030

Figure 5.12 Global Neurological Disorders Market Forecast: Revenue ($bn), AGR (%), 2019-2030

Figure 5.13 Global Diabetes Mellitus Market Forecast: Revenue ($bn), AGR (%), 2019-2030

Figure 5.14 Global Market Forecast for Other Disease Gene Therapies: Revenue ($bn), 2019-2030

Figure 5.15 Global Market for Gene Therapy Drugs: Market Shares by Indication (%), 2025

Figure 5.16 Global Market for Gene Therapy Drugs: Market Shares by Indication (%), 2028

Figure 6.1 Global Gene Therapy Market, by Region: Revenues (%), 2019

Figure 6.2 Global Gene Therapy Market, by Region: Revenues (%), 2025

Figure 6.3 Global Gene Therapy Market, by Region: Revenues (%), 2030

Figure 6.4 North America Market Forecast, Revenue ($bn), AGR (%), 2019-2030

Figure 6.5 Europe Market Forecast, Revenue ($bn), AGR (%), 2019-2030

Figure 6.6 Asia Pacific Market Forecast, Revenue ($bn), AGR (%), 2019-2030

Figure 6.7 Latin America Market Forecast, Revenue ($bn), AGR (%), 2019-2030

Figure 6.8 MEA Market Forecast, Revenue ($bn), AGR (%), 2019-2030

Figure 7.1 Gene Therapies in Clinical Development by Phase, 2019

Figure 7.2 Gene Therapy Market Strategy Analysis

Gene Therapy Market Strategy Analysis

Figure 7.3 Key Take Ways, Challenges and Application of CRISPR Market

Figure 7.4 Impact of CRISPR Technology on the Gene Therapy Market

Figure 8.1 Biogen: Revenue ($mn), 2015-2018

Figure 8.2 Celgene Corporation: Revenue ($mn), AGR (%), 2014-2018

Figure 8.3 Celgene Corporation: Regional Segment Revenue Share (%), 2018

Figure 8.4 GlaxoSmithKline plc: Revenue ($mn), 2014-2018

Figure 8.5 GlaxoSmithKline plc: Business Segment Revenue Share (%), 2018

Figure 8.6 GlaxoSmithKline plc: Pharmaceutical Business Segment Revenue Share (%), 2018

Figure 8.7 GlaxoSmithKline plc: by Region Revenue Share (%), 2018

Figure 8.8 Takeda Pharmaceuticals: Revenue ($bn), 2016-2018

Figure 8.9 Bristol-Myers Squibb Company: Revenue ($bn), AGR (%), 2014-2018

Figure 8.10 Bristol-Myers Squibb Company: Regional Segment Revenue Share (%), 2018

Figure 10.1 Gene Therapy Drug Treatment Market Forecast by Indication: Market Sizes ($bn), 2019, 2025, and 2030

4DMT (4D Molecular Therapeutics)

Abeona

AGTC (Applied Genetics Technologies Corporation)

AMT (Amsterdam Molecular Therapeutics)

AnGes MG

Asklepios BioPharma

AstraZeneca

Audentes Therapeutics

Avalanche Biotech

Bayer Healthcare

Beijing Northland Biotech Co

Benda Pharmaceutical

Benitec Biopharma

BioCancell

Biogen

Biogen Idec

Bluebird Bio

BMS (Bristol-Myers Squibb)

Broad Institute/Whitehead Institute

Celgene

Cell Therapy Catapult

Cellectis

Chiesi Farmaceutici

Clearside Biomedical

Convergence Pharmaceuticals

Daiichi Sankyo

Dimension Therapeutics

Editas Medicine

Fondazione Telethon

Francis Crick Institute

Genable Technologies Ltd

Genethon

GenSight Biologics

GenVec

Google

GSK (GlaxoSmithKline)

Henry Ford Health System

HSCI (Human Stem Cells Institute)

HSR-TIGET (San Raffaele Telethon Institute for Gene Therapy),

ImaginAb

Immune Design Corp

InoCard

Inovio

Intellia Therapeutics

Invetech

Kite Pharma

Kolon Group

Kolon Life Science

Lysogene

Mitsubishi Tanabe Pharma Corporation

Neuralgene

NightstaRx

Northwestern Memorial Hospital

Novartis

OXB (Oxford Biomedica)

Pfizer

PNP Therapeutics

Precision Genome Engineering Inc aka Pregenen

ProNai

Protek Group

Raffaele Hospital

REGENX Biosciences

Renova Therapeutics

Roche

Roszdravnadzor

Sangamo Biosciences

Sanofi

Sarepta Therapeutics

Shanghai Sunway Biotech

Shenzhen SiBiono GeneTech

Sotex Pharm Firm

Spark Therapeutics

SynerGene Therapeutics

Takara Bio

TAP Biosystems

Thermo Fisher Scientific

TissueGene

ToolGen

UC Berkeley

UC San Francisco

uniQure

US Business Innovation Network

Vertex Pharmaceuticals

Vical Incorporated

ViroMed

VM Biopharma

Voyage Therapeutics

List of Organisation Mentioned

ASCO (American Society of Clinical Oncology)

ASI (Agency for Strategic Initiatives)

CAT (Committee for Advanced Therapies)

CBER (Center for Biologics Evaluation and Research)

CHMP (Committee for Medicinal Products for Human Use)

CHOP (The Children’s Hospital of Philadelphia)

DCGI (Drugs Controller General of India)

DHHS (Department of Health and Human Services)

EMA (European Medicines Agency)

FDA (US Food and Drug Administration)

INSERM (Institut National de la Santé et de la Recherche Médicale)

IRB (Institutional Review Boards)

MFDS (Korean Ministry of Food and Drug Safety)

MHLW (Ministry of Health, Labour, and Welfare)

MHRA (Medicines and Healthcare Products Regulatory Agency)

Ministry of Health Commission

NHS (National Health Service)

NICE (the National Institute for Health and Care Excellence)

NIH (National Institutes of Health)

OHRP (Office for Human Research Protections)

PMDA (Pharmaceuticals and Medical Devices Agency)

RCGM (Review Committee of Genetic Manipulation)

Russian Ministry of Healthcare and Social Development

SFDA (State Food and Drug Administration of China)

SMC (Scottish Medicines Consortium)

The Fund for Promotion of Small Innovative Enterprises in Science and Technology

The IGI (Innovative Genomics Initiative)

The Innovative Genomics Initiative

The Walter and Eliza Hall Institute

The Wellcome Trust Sanger Institute

WFH (World Federation of Hemophilia)

WHO (World Health Organization)

Download sample pages

Complete the form below to download your free sample pages for Gene Therapy R&D and Revenue Forecasts 2020-2030

Download sample pages

Complete the form below to download your free sample pages for Gene Therapy R&D and Revenue Forecasts 2020-2030

Case studies

Need customized work?

Report overview

Methodology

Client testimonials

Pharmaceutical industry associations

American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia

Connect with us

Visiongain Pharma

Latest Pharma news

Visiongain Publishes Allergy Immunotherapy Market Report 2023-2033

The global Allergy Immunotherapy market is projected to grow at a CAGR of 7.6% by 2033

31 May 2023

READ

Visiongain Publishes AI-based Clinical Trial Solution Providers Market Report 2023-2033

The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.

26 May 2023

READ

Visiongain Publishes Vaccine Contract Manufacturing Market Report 2023-2033

The global Vaccine Contract Manufacturing Market is projected to grow at a CAGR of 13.2% by 2033

24 May 2023

READ

Visiongain Publishes Cell & Gene Therapy Cold Chain Logistics Market Report 2023-2033

The global Cell & Gene Therapy Cold Chain Logistics market is projected to grow at a CAGR of 15% by 2033

23 May 2023

READ

Industries > Pharma > Gene Therapy R&D and Revenue Forecasts 2020-2030

Back to Pharma Reports

Gene Therapy R&D and Revenue Forecasts 2020-2030

Download sample pages

Related reports

Protein Engineering Market Report 2021-2031

Generic Drugs Market Forecast 2019-2029

Vaccine Contract Manufacturing Market Forecast 2020-2030

Next-Generation Biologics Market Forecast to 2029

Cell Therapy Technologies Market Report 2021-2031

Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Industry and Market 2019-2029

Biobanking Market Forecasts 2019-2029

Global Precision Medicine Market Forecast 2019-2029

Cell-Based Assays Market Report to 2030

Global Stem Cell Technologies and Applications Market 2019-2029

Download sample pages

Share

Connect with us

Latest Pharma news

Visiongain Publishes Allergy Immunotherapy Market Report 2023-2033

Visiongain Publishes AI-based Clinical Trial Solution Providers Market Report 2023-2033

Visiongain Publishes Vaccine Contract Manufacturing Market Report 2023-2033

Visiongain Publishes Cell & Gene Therapy Cold Chain Logistics Market Report 2023-2033

Our Clients